Clinical

The findings suggest that treatment with fluticasone furoate (FF)/umeclidinium (UMEC)/vilanterol (VI) led to improvements and had a similar safety profile to both FF/VI and UMEC/VI regardless of patient chronic mucus hypersecretion status at baseline.

The population-level, mutigenerational study found that both near and distant relatives of women with primary ovarian insufficiency were at a higher risk of the condition compared with matched controls.

Patient-reported outcome (PRO) measures were included in approximately one-half of acne vulgaris and rosacea randomized controlled trials, despite their utility in capturing the patient perspective.

Methotrexate dampens the immune response to vaccines, and a recent study showed that discontinuing treatment for 1 week instead of 2 worked just as well for patients with rheumatoid arthritis getting a flu shot.

Treatment with an angiotensin-converting enzyme (ACE) inhibitor/angiotensin receptor blocker and sodium-glucose cotransporter-2 (SGLT2) inhibitor combination demonstrated better outcomes in kidney failure.

Alvin Wells, MD, PhD, and Jorge Larranaga, MD, highlight the goals of treatment for patients with lupus nephritis.

Key opinion leaders discuss aspects driving care pathways for patients with lupus nephritis.

The investigators of this study compared outcomes between patients who had eosinophilic or noneosinophilic chronic rhinosinusitis with nasal polyps (CRSwNP) by comparing the influence of body mass index (BMI) on each disease subtype.

Social and economic burdens affecting patients with COPD provide significant obstacles to optimizing care.

Jeffrey D. Dunn, PharmD, MBA, leads a panel discussion on disease and treatment landscapes for COPD.

Only 2% of patients with primary sclerosing cholangitis (PSC) received a cholangiocarcinoma diagnosis, and the diagnosis was not early enough for there to be a survival benefit.

An expert explains how Rett syndrome is diagnosed, how commonly it is misdiagnosed, disease progression, and which providers are best positioned to manage a Rett Syndrome patient.

David Lieberman, MD, PhD, describes Rett syndrome, including the various stages, incidence, and potential causes of this disease.

The study offers guidance to clinicians treating the roughly 10% of patients with rare EGFR mutations.

Investigators also confirmed that FGFR2 fusion–positive tumors have a higher expression of FGFR2 but were not associated with higher expression of FGFR1, FGFR3, or FGFR4.

Their findings, say the researchers, offer useful insights into the outcomes and risks of severe disease and mortality in patients who have multiple myeloma (MM) or amyloidosis (AL) with underlying monoclonal gammopathy who contract COVID-19.

A new review has found that increased incidence of chronic kidney disease (CKD) may be seen among patients with nonalcoholic fatty liver disease.

In a sign that value-based care is here to stay, some practices that did not participate in the Oncology Care Model (OCM) have applied for the Enhancing Oncology Model (EOM).

Stemming from recent data on a potential link between major depressive disorder (MDD) and inflammation, research is starting to turn toward alternatives that can treat the disease through anti-inflammatory effects, including ketamine, cannabinoids, and psychedelics.

The Center for Medicare and Medicaid Innovation (CMMI) was a strong collaborator during the Oncology Care Mode (OCM), but the timing of the Enhancing Oncology Model came as a surprise.

Dr Cleary outlines strategies to individualize care for patients diagnosed with upper GI and esophageal cancer.

Laura Bobolts, PharmD, BCOP, and James M. Cleary, MD, provide insights regarding gastroesophageal treatment decisions when FDA labels don’t reflect clinical practice guidelines.

Key social determinants affecting MDD are evaluated by Michael Rothrock, MBA, MHA, and H. Eric Cannon, PharmD, FAMCP.

Expert panelists explore prevalence and disparities of MDD across patient populations.

Researchers found that different factors can negatively impact the Dermatology Life Quality Index scores for adults and adolescents with acne.

A small, prospective, open-label trial found evidence of improved quality of life (QOL) and clinical outcomes among patients with treatment-resistant Sturge-Weber syndrome when they were treated with CBD.

The new report is based on real-world data from a patient registry and shows some patients even regain motor function under treatment with nusinersen for spinal muscular atrophy (SMA).

Detailing findings from the secondary end points of the FIREFISH trial at 24 months, the researchers found that risdiplam treatment was associated with continued improvements in motor function and the achievement of development motor milestones.

Data on empagliflozin in chronic kidney disease (CKD) showed the drug had similar efficacy across subgroups, but more data is needed to really understand the benefit of the drug in CKD, said Jennifer Green, MD, professor of medicine at Duke University School of Medicine, member of Duke Clinical Research Institute, and EMPA-KIDNEY collaborator.

The findings mean that scarring in the esophagus as a result of eosinophilic esophagitis (EoE) can be found earlier, allowing for more targeted intervention.